Share on StockTwits

Stock analysts at Deutsche Bank increased their price objective on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from $6.00 to $17.00 in a report issued on Monday. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price target suggests a potential upside of 83.78% from the company’s current price.

A number of other firms have also recently commented on ACHN. Analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday. Separately, analysts at FBR Capital Markets initiated coverage on shares of Achillion Pharmaceuticals in a research note on Friday. They set an “outperform” rating and a $12.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday, August 11th. They now have a $10.00 price target on the stock, up previously from $5.00. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. Achillion Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $8.90.

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 9.25 on Monday. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $9.94. The stock has a 50-day moving average of $7.3 and a 200-day moving average of $4.58. The company’s market cap is $904.5 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.73 earnings per share for the current fiscal year.

In other Achillion Pharmaceuticals news, Director Michael D. Kishbauch sold 495,812 shares of the stock on the open market in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $9.40, for a total transaction of $4,660,632.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.